Overview

A Study of Trastuzumab in Combination With TS-ONE & Cisplatin in First-line Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer

Status:
Unknown status

Trial end date:
2016-12-01

Target enrollment:

Participant gender:

Summary

The investigators hypothesis is that the combination of TS-ONE with cisplatin and trastuzumab is safe and as effective as combination treatment for HER2 positive gastric cancer.

Phase:

Phase 2

Details

Lead Sponsor:

National University Hospital, Singapore

Collaborator:

National Cancer Centre, Singapore

Treatments:

Cisplatin
Mitogens
Trastuzumab